ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$17.05 USD
-0.03 (-0.18%)
Updated May 3, 2024 04:00 PM ET
After-Market: $17.04 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Brokerage Reports
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 1 - 20 ( 240 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Shifting Focus to ACP-204 and ACP-101, the Key Value Drivers in the Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Enters the Neurodegeneration Space With LRRK2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Positive Data from ADVANCE-2 Potentially Allow Pimavanserin to be Marketed as the First Drug for Negative Symptoms
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ACAD 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Setting Expectations For ADVANCE-2¯Thoughts on Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A